Close Banner
Section Free  - Video Lectures

06. Catatonia Pharmacotherapy: The Role of Benzodiazepines

Published on July 1, 2025 Certification expiration date: July 1, 2028

Scott R. Beach, M.D.

Associate Professor of Psychiatry - Harvard Medical School - Massachusetts General Hospital

Key Points

  • Lorazepam is the preferred benzodiazepine for catatonia and may be more effective intravenously than orally in some cases.
  • Start lorazepam at 2mg every six hours (not q.i.d.) to ensure consistent dosing without overnight gaps.
  • Benzodiazepines for catatonia should be tapered gradually (25% per day inpatient, 25% per week outpatient) to prevent relapse or recurrence.

Free Downloads for Offline Access

  • Free Download PDF File
  • Free Download Video (MP4)
  • Free Download Audio File (MP3)

Slides and Transcript

Slide 1 of 24

Next, we’re going to move into talking about pharmacologic treatment for catatonia, and we’ll start with the role of benzodiazepines. Since our last talk about catatonia, there’s been a number of things that are new with regard to medications and with regard to treatment.

Slide 2 of 24

Probably the biggest thing is that consensus guidelines have been issued by the British Association of Psychopharmacology, and a resource document is forthcoming from the American Psychiatric Association with regard to catatonia in general but also dealing with treatment. So I’ll reference both of these things throughout this talk.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232
  • Wilson, J. E., Oldham, M. A., Francis, A., Perkey, D., Kramer, E., Jiang, S., Yoon, J., Beach, S., Fricchione, G., Gunther, M., Ha, J., Luccarelli, J., Rosen, J., Hamlin, D., Dragonetti, J. D., Gerstenblith, A., Stewart, A. L., Sole, J., & Bourgeois, J. A. (2025). Catatonia: American Psychiatric Association Resource Document. Journal of the Academy of Consultation-Liaison Psychiatry, S2667-2960(25)00482-3. Advance online publication. https://doi.org/10.1016/j.jaclp.2025.05.001
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 3 of 24

One of the key take-aways is that both groups recommend benzodiazepines and ECT as first-line treatments. So there’s pretty good expert consensus agreement on that recommendation.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232
  • Wilson, J. E., Oldham, M. A., Francis, A., Perkey, D., Kramer, E., Jiang, S., Yoon, J., Beach, S., Fricchione, G., Gunther, M., Ha, J., Luccarelli, J., Rosen, J., Hamlin, D., Dragonetti, J. D., Gerstenblith, A., Stewart, A. L., Sole, J., & Bourgeois, J. A. (2025). Catatonia: American Psychiatric Association Resource Document. Journal of the Academy of Consultation-Liaison Psychiatry, S2667-2960(25)00482-3. Advance online publication. https://doi.org/10.1016/j.jaclp.2025.05.001

Slide 4 of 24

The British Association of Psychopharmacology guidelines do give a few exceptions for this. For example, in cases of clozapine withdrawal catatonia, clozapine is recommended as first line. And they note that in chronic milder catatonia in the context of schizophrenia, there is some anecdotal evidence for clozapine sometimes in combination with benzodiazepines.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 5 of 24

They also note that the choice between benzodiazepines and ECT should weigh things like side effect profile, the availability of ECT and whether there’s an underlying condition that itself is responsive to ECT.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232

Slide 6 of 24

A few reminders about benzodiazepines in catatonia more generally. As I mentioned before, when we were talking about the challenge, lorazepam remains the preferred agent. Diazepam is really the other benzodiazepine that’s been shown to be effective. Both of these have the advantage of being given via multiple routes – intravenous, intramuscular, oral.
References:
  • Fernández Hurst, N., Zanetti, S. R., Baez, N. S., Bibolini, M. J., Bouzat, C. B., & et al. (2017). Diazepam treatment reduces inflammatory cells and mediators in the central nervous system of rats with experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 313, 145-151. https://doi.org/10.1016/j.jneuroim.2017.09.012
  • Gunther, M., Luccarelli, J., & Beach, S. (2025). Revisiting the lorazepam challenge: An algorithm for clinical-decision making. General Hospital Psychiatry, 93(1). https://doi.org/10.1016/j.genhosppsych.2025.01.016
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 7 of 24

And it’s important to keep in mind that many other benzodiazepines including clonazepam and midazolam do not seem to be as effective for adults. We don’t know for sure why that is. There are many theories. Part of the difference may lie in the preference of diazepam and lorazepam for the GABA-A receptor which may be more involved in catatonia.
References:
  • Gunther, M., Luccarelli, J., & Beach, S. (2025). Revisiting the lorazepam challenge: An algorithm for clinical-decision making. General Hospital Psychiatry, 93(1). https://doi.org/10.1016/j.genhosppsych.2025.01.016
  • Suchandra, H. H., Reddi, V. S. K., Aandi Subramaniyam, B., & Muliyala, K. P. (2020). Revisiting lorazepam challenge test: Clinical response with dose variations and utility for catatonia in a psychiatric emergency setting. Australian & New Zealand Journal of Psychiatry, 55(10), 993-1004. https://doi.org/10.1177/0004867420968915

Slide 8 of 24

There’s another theory having to do with anti-inflammatory properties of diazepam and lorazepam, and their specific actions on translocator protein which may be unique. But we still have a lot to understand about why those two benzodiazepines in particular seem to be so effective.
References:
  • Fernández Hurst, N., Zanetti, S. R., Baez, N. S., Bibolini, M. J., Bouzat, C. B., & et al. (2017). Diazepam treatment reduces inflammatory cells and mediators in the central nervous system of rats with experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 313, 145-151. https://doi.org/10.1016/j.jneuroim.2017.09.012
  • Gunther, M., Luccarelli, J., & Beach, S. (2025). Revisiting the lorazepam challenge: An algorithm for clinical-decision making. General Hospital Psychiatry, 93(1). https://doi.org/10.1016/j.genhosppsych.2025.01.016
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 9 of 24

The British guidelines for benzodiazepines emphasize that lorazepam is the preferred agent. They don’t necessarily offer a preference in terms of the route. Our experience would say that intravenous lorazepam tends to work better than oral lorazepam. I’ve seen many patients who don’t respond to doses of oral lorazepam, but respond pretty quickly to intravenous lorazepam.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232

Slide 10 of 24

The British guidelines define an adequate trial of benzodiazepines as occurring when either the catatonia is adequately treated, the titration has been stopped due to side effects or the dose has reached at least 16 mg per day.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 11 of 24

One thing that I’m commonly asked is how we decide the initial dose of benzodiazepines to use after a lorazepam challenge. Unfortunately, there is essentially no data to guide us here, and so it’s really just based on clinical intuition and anecdotal experience but generally, I’m going to start a dose of 2 mg every six hours as my default. That is a dose of 8 mg a day. I always write that as every six hours rather than q.i.d. because if you write an order as q.i.d. or t.i.d. you’re giving the patient a long period of time overnight where they won’t get a dose, whereas you want patients with catatonia to get consistent and regular doses.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232
  • Wilson, J. E., Oldham, M. A., Francis, A., Perkey, D., Kramer, E., Jiang, S., Yoon, J., Beach, S., Fricchione, G., Gunther, M., Ha, J., Luccarelli, J., Rosen, J., Hamlin, D., Dragonetti, J. D., Gerstenblith, A., Stewart, A. L., Sole, J., & Bourgeois, J. A. (2025). Catatonia: American Psychiatric Association Resource Document. Journal of the Academy of Consultation-Liaison Psychiatry, S2667-2960(25)00482-3. Advance online publication. https://doi.org/10.1016/j.jaclp.2025.05.001

Slide 12 of 24

If somebody has what I would think about as more severe catatonia, then I may start them at 2 mg every four hours. If somebody has less severe catatonia, I may think about starting them at 2 mg every eight hours but almost always in that initial range.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232
  • Wilson, J. E., Oldham, M. A., Francis, A., Perkey, D., Kramer, E., Jiang, S., Yoon, J., Beach, S., Fricchione, G., Gunther, M., Ha, J., Luccarelli, J., Rosen, J., Hamlin, D., Dragonetti, J. D., Gerstenblith, A., Stewart, A. L., Sole, J., & Bourgeois, J. A. (2025). Catatonia: American Psychiatric Association Resource Document. Journal of the Academy of Consultation-Liaison Psychiatry, S2667-2960(25)00482-3. Advance online publication. https://doi.org/10.1016/j.jaclp.2025.05.001
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 13 of 24

When I think about escalating a dose of benzodiazepines, I often think in total daily doses first rather than in specifically how I’m going to write the order, and how I’m going to space the medication. So if I’ve come to a decision to increase the total daily dose because I think the response is not as strong as it could be, then in order to decide whether I’m going to increase the amount of benzodiazepines that they’re given at each dose or whether I’m going to increase the frequency, I will often look at the pattern of response.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232
  • Wilson, J. E., Oldham, M. A., Francis, A., Perkey, D., Kramer, E., Jiang, S., Yoon, J., Beach, S., Fricchione, G., Gunther, M., Ha, J., Luccarelli, J., Rosen, J., Hamlin, D., Dragonetti, J. D., Gerstenblith, A., Stewart, A. L., Sole, J., & Bourgeois, J. A. (2025). Catatonia: American Psychiatric Association Resource Document. Journal of the Academy of Consultation-Liaison Psychiatry, S2667-2960(25)00482-3. Advance online publication. https://doi.org/10.1016/j.jaclp.2025.05.001

Slide 14 of 24

If somebody is responding to the dose of benzodiazepine, for example, 2 mg q.6 but I’m noticing that at the end of the six hours their symptoms are getting much worse, that’s a time when I’m going to think about increasing the frequency. So I might go to 2 mg q.4. Whereas, if somebody is not having as much of a response as I would like to each dose that they’re receiving, then I might think about increasing the dose that they’re given.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232
  • Wilson, J. E., Oldham, M. A., Francis, A., Perkey, D., Kramer, E., Jiang, S., Yoon, J., Beach, S., Fricchione, G., Gunther, M., Ha, J., Luccarelli, J., Rosen, J., Hamlin, D., Dragonetti, J. D., Gerstenblith, A., Stewart, A. L., Sole, J., & Bourgeois, J. A. (2025). Catatonia: American Psychiatric Association Resource Document. Journal of the Academy of Consultation-Liaison Psychiatry, S2667-2960(25)00482-3. Advance online publication. https://doi.org/10.1016/j.jaclp.2025.05.001
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 15 of 24

So 16 mg per day in my mind is a moderate dose, but I would continue to push lorazepam beyond that dose as long as patients were tolerating it and there was no evidence of respiratory compromise.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232
  • Wilson, J. E., Oldham, M. A., Francis, A., Perkey, D., Kramer, E., Jiang, S., Yoon, J., Beach, S., Fricchione, G., Gunther, M., Ha, J., Luccarelli, J., Rosen, J., Hamlin, D., Dragonetti, J. D., Gerstenblith, A., Stewart, A. L., Sole, J., & Bourgeois, J. A. (2025). Catatonia: American Psychiatric Association Resource Document. Journal of the Academy of Consultation-Liaison Psychiatry, S2667-2960(25)00482-3. Advance online publication. https://doi.org/10.1016/j.jaclp.2025.05.001

Slide 16 of 24

Another recommendation from the British guidelines that I think is really important for prescribers to be aware of is the idea that benzodiazepines for catatonia should not be stopped abruptly. They should be tapered and generally the taper should be quite gradual. The speed of the taper really depends on balancing the benefits and the risks of withdrawal, but what we find in patients with catatonia is that the quicker the taper, the more likelihood there is for recurrence or relapse.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 17 of 24

On the inpatient settings, we usually taper by no more than 25% per day and commonly much slower than that. And in the outpatient settings, we often taper by no more than 25% per week and again often much more slowly. It’s important to keep in mind that there are some patients who may require maintenance on benzodiazepines indefinitely and the risk of catatonia recurrence should be weighed against the other risks of benzodiazepines.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232

Slide 18 of 24

I think in general as a field we’ve become scared a little bit of benzodiazepines and while I think there are good reasons to be concerned about the use of benzodiazepines, there are also many conditions which respond very well to benzodiazepines and catatonia is certainly number 1 on that list. So I think there are patients who have two or three episodes of catatonia, and that’s an argument for them to be maintained indefinitely on low-dose lorazepam as long as there are no major contraindications.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 19 of 24

There’s also some evidence that attempting to switch from maintenance lorazepam to a longer-acting benzodiazepine such as clonazepam for maintenance may also result in relapse. So again, there seems to be something that’s unique about lorazepam and probably diazepam as well. If catatonia does relapse during the benzodiazepine taper, it’s important to restore a higher dose and then proceed with a more gradual taper.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232

Slide 20 of 24

The other thing that I would highlight in terms of tapering on the inpatient setting is that we think of intravenous lorazepam as being sort of twice as potent for catatonia as compared to oral lorazepam. So when you’re getting to the point where you want to convert from intravenous lorazepam to oral lorazepam, we will generally increase the dose of the oral lorazepam that we’re using because if we just do a straight conversion from 16 mg a day of IV lorazepam to 16 mg a day of p.o. lorazepam, you may effectively be cutting the dose in half and that may be an increased risk for relapse.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 21 of 24

So in that case, we will often bump up the p.o. dose to something like 20 or 24 mg of p.o. lorazepam a day before we continue the gradual taper using oral lorazepam. Generally, on the inpatient settings, when you’re thinking about converting from intravenous to p.o. lorazepam, you want to have had a sustained response for about 48 hours on intravenous lorazepam before you would even think about making that conversion.
References:
  • Rogers, J. P., Oldham, M. A., Fricchione, G., Northoff, G., Ellen Wilson, J., Mann, S. C., Francis, A., Wieck, A., Elizabeth Wachtel, L., Lewis, G., Grover, S., Hirjak, D., Ahuja, N., Zandi, M. S., Young, A. H., Fone, K., Andrews, S., Kessler, D., Saifee, T., Gee, S., … David, A. S. (2023). Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 37(4), 327–369. https://doi.org/10.1177/02698811231158232

Slide 22 of 24

Some newer data on benzodiazepines have suggested that a few additional predictors of nonresponse to benzodiazepines may include a longer duration of catatonia. That’s been thought to be the case for a while. The presence of mitgehen or immobility specifically may predict nonresponse to benzodiazepines. And then data that you’re unlikely to have but is important for research purposes is that a lower volume of the right medial orbitofrontal cortex has also been suggested to be a predictor of nonresponse to benzodiazepines.
References:
  • Badinier, J., Lopes, R., Mastellari, T., Fovet, T., Williams, S. C. R., Pruvo, J. P., & Amad, A. (2024). Clinical and neuroimaging predictors of benzodiazepine response in catatonia: A machine learning approach. Journal of Psychiatric Research, 172, 300–306. https://doi.org/10.1016/j.jpsychires.2024.02.039
  • Zwiebel, S., & De Leon, J. (2024). Maintenance treatment of catatonia with benzodiazepines: A case series and literature review. Neuropsychopharmacologia Hungarica, 26(4), 243-260.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 23 of 24

To summarize, some key points from this section: Benzodiazepines especially lorazepam and diazepam really remain the first-line treatment strategies for catatonia. Benzodiazepines should be tapered slowly rather than abruptly stopped in order to mitigate against worsening or recurrence.

Slide 24 of 24

Patients with a longer duration of catatonia, those demonstrating mitgehen or immobility and those with a lower volume of the right medial orbitofrontal cortex may be less likely to respond to benzodiazepines.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Learning Objectives:

After completing this activity, the learner will be able to:

  1. Recognize the clinical features of catatonia using validated assessment tools.
  2. Implement evidence-based pharmacologic interventions for catatonia.
  3. Identify and manage medical complications associated with catatonia.

Original Release Date: July 1, 2025

Expiration Date: July 1, 2028

Expert: Scott Beach, M.D.

Medical Editor: Flavio Guzmán, M.D. 

Relevant Financial Disclosures: 

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

  1. View the required educational content provided on this course page.

  2. Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.

  3. Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Free Files
Success!
Check your inbox, we sent you all the materials there.
Continue in the website
Instant access modal

Become a Bronze, Silver, Gold, Bronze extended, Silver extended or Gold extended Member.

2025–26 Psychopharmacology CME Program

Unlock up to 155 CME Credits, including 40 SA CME Credits.